Search company, investor...

Aurelium BioPharma

Founded Year



Other Investors | Alive

About Aurelium BioPharma

Aurelium BioPharma Inc is the therapeutics company using an integrated Suite of leadingedge proteomics tools that integrate validated targets and complementary diagnostics to deliver therapeutic solutions rapidly and cost effectively‚ Their SMART TM proteomics covers several enabling and technology platforms that aims to allow the company to rapidly identify and validate a large number of druggable protein targets‚ Aureliums immediate focus is the development therapeutics and diagnostic tools for the treatment of drugresistant cancers for which there is currently no treatment available

Headquarters Location

3090 Le Carrefour Blvd. Suite 720

Laval, Quebec, H7T 2J7,



Missing: Aurelium BioPharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Aurelium BioPharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Aurelium BioPharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Aurelium BioPharma is included in 1 Expert Collection, including Cancer.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Aurelium BioPharma Patents

Aurelium BioPharma has filed 3 patents.

patents chart

Application Date

Grant Date


Related Topics




Epidermal nevi, neoplasms, cysts, Clusters of differentiation, Immunology, Cytokines, Monoclonal antibodies


Application Date


Grant Date



Related Topics

Epidermal nevi, neoplasms, cysts, Clusters of differentiation, Immunology, Cytokines, Monoclonal antibodies



Aurelium BioPharma Frequently Asked Questions (FAQ)

  • When was Aurelium BioPharma founded?

    Aurelium BioPharma was founded in 1998.

  • Where is Aurelium BioPharma's headquarters?

    Aurelium BioPharma's headquarters is located at 3090 Le Carrefour Blvd., Laval.

  • What is Aurelium BioPharma's latest funding round?

    Aurelium BioPharma's latest funding round is Other Investors.

  • Who are the investors of Aurelium BioPharma?

    Investors of Aurelium BioPharma include BDC Venture Capital.

  • Who are Aurelium BioPharma's competitors?

    Competitors of Aurelium BioPharma include Aphios, Fujirebio, Alethia BioTherapeutics, Pique Therapeutics, Raptor Pharmaceutical Corp. and 14 more.

Compare Aurelium BioPharma to Competitors


Vybion is a developer and manufacturer of recombinant proteins for therapeutic and diagnostic applications. It uses its technologies along with a highly skilled staff to develop therapeutics, vaccines, diagnostics and bioavailability for pharmaceutical and biotechnology companies.

Arisyn Therapeutics

Arisyn Therapeutics Inc. is a biotechnology company focused on the development of first in class inhibitors of infectious disease and cancer. Arisyn possesses a portfolio of small molecule compounds that will be developed to treat Human Immunodeficiency Virus-Type 1 (HIV-1), Human Immunodeficiency Virus-Type 2 (HIV-2), Human T-Lymphotropic Virus-Type 1 (HTLV-1), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Herpes Simplex Virus-Type 2 (HSV-2). Arisyn will perform all necessary studies required to develop these therapeutic agents through Phase 1 and Phase 2 human clinical trials.


ATNT is a biotech company which develops cross-disciplinary engineering methods, to find the most effective molecular targets for treatment of complex human disorders.


CellXplore is a new, biotechnology company engaged in the development of biomarker-based in vitro diagnostic assays for cancer, initially focusing on breast cancer. Although mammography is an effective screening test for early detection, there is a need for a simple, reliable and sensitive biomarker-based in vitro assay that can be used to stage and characterize breast cancer.nThe company was formed to commercialize groundbreaking discoveries demonstrating up-regulation of the ubiquitin-proteasome pathway in cancerous breast tissue, providing the capability for the noninvasive detection of breast cancer and the ability to monitor the efficacy of chemotherapeutic interventions.nCellXplore's platform technology is not restricted to breast cancer in vitro diagnostics alone, nor is it restricted to cancer diagnostics alone. Beyond cancer, CellXplore is already investigating whether similar blood sample biomarkers can be identified for the early diagnosis of several major debilitating diseases such as muscle wasting, Alzheimer's disease, Parkinson's disease and inflammatory diseases.


Adriacell s.r.l is a biotech company focused in oncology pharmaceuticals founded in Basovizza (Trieste) in March 2004 by Prof. Christian Kuehne, an Austrian citizen.nThe company is leveraging its efforts and scientific expertise to successfully solve important worldwide health problems; in particular, it has been striving to develop a new class of anti-tumour therapeutics and to create a series of powerful diagnostics for the early detection of cancer progression. The company is also developing new and highly powerful delivery solutions through small molecules as the basis for a new class of anti-infective drugs.nAdriaCell owns a patented system that can be used for the study of events subsequent to DNA double strand breaks, a very important issue for cancer research and diagnostics. Adriacell is currently evaluating a new class of therapeutics for cancer; its main lead compound is about to enter the pharmacokinetic and toxicology phases.nAdriacell Vision is to become a leader biotech drug development company concentrated in the development of solutions (treatment and diagnostics) for tumours characterized by low probability of survival for patients and of anti infective agents. Thanks to future developments in research and test activities Adriacell solutions will hopefully become useful in a wider range of pathologies.


Spaltudaq Corporation, a privately-held biotechnology company based in Seattle, is focused on developing therapeutic antibodies for the treatment of inflammation, infectious disease and cancer. Our technology harnesses the power of the human immune system to identify tumor-specific or pathogen-specific monoclonal antibodies from human tissue samples.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.